NBY logo

NovaBay Pharmaceuticals (NBY) Cash From Financing

Annual CFF

$1.91 M
-$2.72 M-58.77%

December 1, 2023

Summary

Performance

1-Year Change

-58.77%

3-Year Change

-80.43%

5-Year Change

-65.87%

15-Year Change

+850.25%

NBY Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

40.13%
NBY annual cash flow from financing activities is higher than 40.13% of companies in Healthcare sector

High & Low

All-time High

$19.42 M
NBY annual cash flow from financing activities is currently -90.17% below its historical high of $19.42 million

3-Year Low

$1.91 M
NBY annual cash flow from financing activities is currently at its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 1, 2023
NBY previous annual earnings announcement was published on Dec 1, 2023

Next Annual Earnings Report Date

N/A
NBY next annual earnings announcement has not yet been scheduled

OtherNBYcash flowmetrics:

Annual CFI

-$19.00 K
NBY annual cash flow from investing activities is -$19.00 thousand

Annual CFO

-$4.13 M
NBY annual cash flow from operations is -$4.13 million

Annual FCF

-$4.15 M
NBY annual free cash flow is -$4.15 million

Annual CAPEX

$19.00 K
NBY annual capital expenditures is $19.00 thousand

Quarterly CFF

$2.09 M
+$2.58 M+524.59%

September 1, 2024

Summary

Performance

3-Month Change

+524.59%

1-Year Change

+462.05%

3-Year Change

-16.87%

5-Year Change

-16.87%

NBY Quarterly CFF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

70.67%
NBY quarterly cash flow from financing activities is higher than 70.67% of companies in Healthcare sector

High & Low

All-time High

$18.37 M
NBY quarterly cash flow from financing activities is currently -88.63% below its historical high of $18.37 million

3-Year Low

-$597.00 K

Earnings dates

Last Quarterly Earnings Report Date

Sep 1, 2024
NBY previous earnings announcement was published on Sep 1, 2024

Next Quarterly Earnings Report Date

N/A
NBY next earnings announcement has not yet been scheduled

OtherNBYcash flowmetrics:

Quarterly CFI

-$2000.00
NBY quarterly cash flow from investing activities is -$2000.00

Quarterly CFO

-$2.06 M
NBY quarterly cash flow from operations is -$2.06 million

Quarterly FCF

-$2.06 M
NBY quarterly free cash flow is -$2.06 million

Quarterly CAPEX

$2000.00
NBY quarterly capital expenditures is $2000.00

TTM CFF

$974.00 K
+$2.67 M+157.57%

September 1, 2024

Summary

Performance

3-Month Change

+157.57%

1-Year Change

-80.41%

3-Year Change

-86.57%

5-Year Change

-86.57%

NBY TTM CFF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

32.84%
NBY TTM cash flow from financing activities is higher than 32.84% of companies in Healthcare sector

High & Low

All-time High

$22.13 M
NBY TTM cash flow from financing activities is currently -95.60% below its historical high of $22.13 million

3-Year Low

-$1.69 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 1, 2024
NBY previous earnings announcement was published on Sep 1, 2024

Next Quarterly Earnings Report Date

N/A
NBY next earnings announcement has not yet been scheduled

OtherNBYcash flowmetrics:

TTM CFI

$1.06 M
NBY TTM cash flow from investing activities is $1.06 million

TTM CFO

-$4.80 M
NBY TTM cash flow from operations is -$4.80 million

TTM FCF

-$4.81 M
NBY TTM free cash flow is -$4.81 million

TTM CAPEX

$9000.00
NBY TTM capital expenditures is $9000.00

Cash From Financing Formula

CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities

NBY Cash From Financing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-58.8%+462.1%-80.4%
3 y3 years-80.4%-16.9%-86.6%
5 y5 years-65.9%-16.9%-86.6%

NBY Cash From Financing Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-88.6%at low-85.9%+449.9%-94.2%+157.6%
5 y5-year-88.6%at low-85.9%+419.4%-94.2%+157.6%
alltimeall time-90.2%+754.1%-88.6%+419.4%-95.6%+157.6%

NovaBay Pharmaceuticals Cash From Financing History

DateAnnualQuarterlyTTM
Sep 2024
-
$2.09 M(-524.6%)
$974.00 K(-157.6%)
Jun 2024
-
-$492.00 K(-17.6%)
-$1.69 M(-228.9%)
Mar 2024
-
-$597.00 K(+2196.2%)
$1.31 M(-31.3%)
Dec 2023
$1.91 M(-58.8%)
-$26.00 K(-95.5%)
$1.91 M(-61.6%)
Sep 2023
-
-$577.00 K(-123.0%)
$4.97 M(-31.4%)
Jun 2023
-
$2.51 M(>+9900.0%)
$7.25 M(+53.0%)
Mar 2023
-
$0.00(-100.0%)
$4.74 M(+2.3%)
Dec 2022
$4.63 M(-72.4%)
$3.04 M(+78.2%)
$4.63 M(-71.7%)
Sep 2022
-
$1.70 M(>+9900.0%)
$16.39 M(+10.0%)
Jun 2022
-
$0.00(-100.0%)
$14.91 M(-10.6%)
Mar 2022
-
-$105.00 K(-100.7%)
$16.68 M(-0.6%)
Dec 2021
$16.79 M(+72.0%)
$14.79 M(+6655.7%)
$16.79 M(+739.9%)
Sep 2021
-
$219.00 K(-87.7%)
$2.00 M(-74.3%)
Jun 2021
-
$1.77 M(>+9900.0%)
$7.79 M(-23.0%)
Mar 2021
-
$0.00(-100.0%)
$10.13 M(+3.7%)
Dec 2020
$9.76 M(-16.6%)
$5000.00(-99.9%)
$9.76 M(+7.2%)
Sep 2020
-
$6.01 M(+46.4%)
$9.10 M(-8.4%)
Jun 2020
-
$4.11 M(-1228.6%)
$9.94 M(+19.0%)
Mar 2020
-
-$364.00 K(-44.3%)
$8.35 M(-28.6%)
Dec 2019
$11.70 M(+109.1%)
-$654.00 K(-109.5%)
$11.70 M(-5.3%)
Sep 2019
-
$6.85 M(+171.9%)
$12.36 M(+124.5%)
Jun 2019
-
$2.52 M(-15.5%)
$5.50 M(+84.8%)
Mar 2019
-
$2.98 M(>+9900.0%)
$2.98 M(-46.8%)
Dec 2018
$5.60 M(+2684.6%)
$0.00(0.0%)
$5.60 M(-1.1%)
Sep 2018
-
$0.00(-100.0%)
$5.66 M(-2.5%)
Jun 2018
-
-$6000.00(-100.1%)
$5.81 M(-0.8%)
Mar 2018
-
$5.60 M(+8520.0%)
$5.85 M(+2811.4%)
Dec 2017
$201.00 K(-99.0%)
$65.00 K(-55.5%)
$201.00 K(-79.8%)
Sep 2017
-
$146.00 K(+284.2%)
$994.00 K(-90.7%)
Jun 2017
-
$38.00 K(-179.2%)
$10.67 M(-30.6%)
Mar 2017
-
-$48.00 K(-105.6%)
$15.38 M(-20.8%)
Dec 2016
$19.42 M(+24.5%)
$858.00 K(-91.3%)
$19.42 M(-12.2%)
Sep 2016
-
$9.82 M(+107.0%)
$22.13 M(+75.0%)
Jun 2016
-
$4.75 M(+18.8%)
$12.64 M(-15.4%)
Mar 2016
-
$3.99 M(+11.9%)
$14.94 M(-4.2%)
Dec 2015
$15.60 M
$3.57 M(+958.8%)
$15.60 M(+25.3%)
DateAnnualQuarterlyTTM
Sep 2015
-
$337.00 K(-95.2%)
$12.45 M(-0.2%)
Jun 2015
-
$7.04 M(+51.4%)
$12.47 M(+127.5%)
Mar 2015
-
$4.65 M(+1007.9%)
$5.48 M(-25.8%)
Dec 2014
$7.39 M(-20.8%)
$420.00 K(+17.0%)
$7.39 M(-47.2%)
Sep 2014
-
$359.00 K(+603.9%)
$13.98 M(-9.5%)
Jun 2014
-
$51.00 K(-99.2%)
$15.46 M(-2.5%)
Mar 2014
-
$6.56 M(-6.6%)
$15.85 M(+70.0%)
Dec 2013
$9.33 M(-1.5%)
$7.02 M(+283.1%)
$9.33 M(-11.1%)
Sep 2013
-
$1.83 M(+309.8%)
$10.49 M(+5.2%)
Jun 2013
-
$447.00 K(+1390.0%)
$9.98 M(+4.6%)
Mar 2013
-
$30.00 K(-99.6%)
$9.54 M(+0.7%)
Dec 2012
$9.47 M(+101.5%)
$8.19 M(+523.0%)
$9.47 M(+572.7%)
Sep 2012
-
$1.31 M(>+9900.0%)
$1.41 M(-70.3%)
Jun 2012
-
$7000.00(-120.0%)
$4.74 M(+0.1%)
Mar 2012
-
-$35.00 K(-128.7%)
$4.73 M(+0.6%)
Dec 2011
$4.70 M(-1709.9%)
$122.00 K(-97.4%)
$4.70 M(+3.7%)
Sep 2011
-
$4.64 M(>+9900.0%)
$4.53 M(-2218.2%)
Jun 2011
-
$0.00(-100.0%)
-$214.00 K(-25.7%)
Mar 2011
-
-$64.00 K(+39.1%)
-$288.00 K(-1.4%)
Dec 2010
-$292.00 K(-118.1%)
-$46.00 K(-55.8%)
-$292.00 K(-18.2%)
Sep 2010
-
-$104.00 K(+40.5%)
-$357.00 K(-122.2%)
Jun 2010
-
-$74.00 K(+8.8%)
$1.61 M(+1.0%)
Mar 2010
-
-$68.00 K(-38.7%)
$1.59 M(-1.1%)
Dec 2009
$1.61 M(+582.2%)
-$111.00 K(-106.0%)
$1.61 M(-1.0%)
Sep 2009
-
$1.86 M(-2168.9%)
$1.63 M(-1003.3%)
Jun 2009
-
-$90.00 K(+76.5%)
-$180.00 K(-415.8%)
Mar 2009
-
-$51.00 K(-46.3%)
$57.00 K(-75.8%)
Dec 2008
$236.00 K(-98.7%)
-$95.00 K(-269.6%)
$236.00 K(-98.7%)
Sep 2008
-
$56.00 K(-61.9%)
$18.70 M(+1.6%)
Jun 2008
-
$147.00 K(+14.8%)
$18.41 M(-0.9%)
Mar 2008
-
$128.00 K(-99.3%)
$18.58 M(+3.4%)
Dec 2007
$17.97 M(+418.7%)
$18.37 M(-7883.9%)
$17.97 M(-4581.0%)
Sep 2007
-
-$236.00 K(-173.3%)
-$401.00 K(+143.0%)
Jun 2007
-
$322.00 K(-166.1%)
-$165.00 K(-66.1%)
Mar 2007
-
-$487.00 K
-$487.00 K
Dec 2006
$3.46 M(+36.7%)
-
-
Dec 2005
$2.53 M
-
-

FAQ

  • What is NovaBay Pharmaceuticals annual cash flow from financing activities?
  • What is the all time high annual CFF for NovaBay Pharmaceuticals?
  • What is NovaBay Pharmaceuticals annual CFF year-on-year change?
  • What is NovaBay Pharmaceuticals quarterly cash flow from financing activities?
  • What is the all time high quarterly CFF for NovaBay Pharmaceuticals?
  • What is NovaBay Pharmaceuticals quarterly CFF year-on-year change?
  • What is NovaBay Pharmaceuticals TTM cash flow from financing activities?
  • What is the all time high TTM CFF for NovaBay Pharmaceuticals?
  • What is NovaBay Pharmaceuticals TTM CFF year-on-year change?

What is NovaBay Pharmaceuticals annual cash flow from financing activities?

The current annual CFF of NBY is $1.91 M

What is the all time high annual CFF for NovaBay Pharmaceuticals?

NovaBay Pharmaceuticals all-time high annual cash flow from financing activities is $19.42 M

What is NovaBay Pharmaceuticals annual CFF year-on-year change?

Over the past year, NBY annual cash flow from financing activities has changed by -$2.72 M (-58.77%)

What is NovaBay Pharmaceuticals quarterly cash flow from financing activities?

The current quarterly CFF of NBY is $2.09 M

What is the all time high quarterly CFF for NovaBay Pharmaceuticals?

NovaBay Pharmaceuticals all-time high quarterly cash flow from financing activities is $18.37 M

What is NovaBay Pharmaceuticals quarterly CFF year-on-year change?

Over the past year, NBY quarterly cash flow from financing activities has changed by +$2.67 M (+462.05%)

What is NovaBay Pharmaceuticals TTM cash flow from financing activities?

The current TTM CFF of NBY is $974.00 K

What is the all time high TTM CFF for NovaBay Pharmaceuticals?

NovaBay Pharmaceuticals all-time high TTM cash flow from financing activities is $22.13 M

What is NovaBay Pharmaceuticals TTM CFF year-on-year change?

Over the past year, NBY TTM cash flow from financing activities has changed by -$4.00 M (-80.41%)